FOLH1 and neoplasm: Kind et al. [12] retrospectively analysed the prognostic value of the RECIP framework in mCRPC patients undergoing 177Lu-PSMA radioligand therapy, with tumour burden quantified semi-automatically using the methodology developed by Seifert et al. [15].